However, the IDH1 gene is rarely mutated in cancers other than gliomas and is therefore not a likely candidate as a causative factor for the CpG methylator phenotype in breast cancers (Kandoth et al., 2013). This evidence concerns the gene IDH1 and central nervous system cancer.